Also targeted therapies like TKIs depend on achieving threshold intratumoral levels simply because evidenced simply by pharmacokinetic and pharmacogenomics research [27,41,42]

Also targeted therapies like TKIs depend on achieving threshold intratumoral levels simply because evidenced simply by pharmacokinetic and pharmacogenomics research [27,41,42]. Considering that small-molecule anti-cancer therapies need a threshold of…